Semaglutide vs Tirzepatide: A Researcher’s Comparison of GLP-1 and Dual-Incretin Agonists

By Sam Smith

The SURMOUNT-5 head-to-head trial landed in early 2025 with a result that settled an argument researchers had been having for three years: tirzepatide outperformed semaglutide 2.4 mg by roughly 47% on total weight loss — 20.2% vs 13.7% of body weight over 72 weeks. That's not a marginal difference. It reshapes how anyone serious about incretin pharmacology thinks about these two molecules, and it raises the obvious follow-up question: what exactly is tirzepatide doing that semaglutide isn't?

The short answer is receptor coverage. Semaglutide is a selective GLP-1 receptor agonist — it mimics glucagon-like peptide-1 with high fidelity and was specifically engineered by Novo Nordisk with two amino acid substitutions (positions 8 and 34) to resist DPP-4 cleavage, giving it a plasma half-life of roughly seven days. Tirzepatide, by contrast, is a dual GIP/GLP-1 agonist — a single molecule that activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously. The GIPR engagement appears to amplify weight loss beyond what GLP-1 agonism alone achieves, though the exact mechanism is still being worked out. Worth noting: GIP was once dismissed as a minor incretin player, which makes tirzepatide's efficacy profile one of the more humbling examples of how incomplete our receptor-level intuitions can be.

This guide walks through the receptor-level differences between these two molecules, what the full trial dataset shows on weight reduction, glycemic control, muscle preservation, and GI side effects, and what researchers need to consider when designing comparison studies. Every data point links to its primary PubMed source — no secondary sources, no manufacturer white papers.

What is semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist engineered to resist degradation by dipeptidyl peptidase-4 and to bind albumin in circulation, giving it a half-life around one week. According to the original PubMed-indexed Novo Nordisk pharmacology paper, semaglutide has two amino acid substitutions compared to human GLP-1, with the substitutions at positions 8 (aminoisobutyric acid) and 34 (arginine) being responsible for that extended pharmacokinetic profile. The molecule was first approved for type 2 diabetes in 2017 (Ozempic) and for chronic weight management in 2021 (Wegovy at 2.4 mg subcutaneously once weekly).

What is tirzepatide?

Tirzepatide is the first dual incretin receptor agonist to reach the market. According to the discovery paper indexed in PubMed, tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist that binds and activates both receptors. The molecule is biased toward the GIP receptor relative to the native GIP ligand and behaves like a GLP-1 mimic at the GLP-1 receptor. Eli Lilly secured FDA approval for tirzepatide in type 2 diabetes (Mounjaro) in May 2022 and in chronic weight management (Zepbound) in November 2023, with weekly subcutaneous dosing escalated from 2.5 mg up to 15 mg.

Key mechanistic differences between semaglutide and tirzepatide

The receptor profile is the single biggest difference. Semaglutide is a pure glucagon-like peptide-1 mimic; the dual agonist tirzepatide activates both GIP and the GLP-1 receptor. GLP-1 signalling in the hypothalamus, brainstem, and pancreatic islet drives satiety, slower gastric emptying, glucose-dependent insulin secretion, suppressed glucagon release, and lower blood sugar levels in people with type 2 diabetes mellitus. GIP adds a complementary insulinotropic effect at the pancreatic beta cell and appears to modify adipocyte lipid handling and central appetite signalling in ways that are still being mapped. Both molecules are also approved to treat type 2 diabetes; tirzepatide once weekly is also approved for weight management in the United States.

The structural details matter for researchers comparing the two. Semaglutide retains the 31-residue GLP-1 backbone with two substitutions and a C18 fatty diacid linker for albumin binding. Tirzepatide is a 39-residue chimeric peptide whose core sequence derives from native GIP but whose pharmacology is largely GLP-1-driven at the GLP-1 receptor. The two molecules are not interchangeable analogues; they are members of different receptor-pharmacology classes.

Weight loss outcomes: which is better for weight loss?

In direct comparison, tirzepatide produces larger reductions in body weight than semaglutide at the doses studied. In the STEP-1 trial of semaglutide 2.4 mg subcutaneously once weekly, the New England Journal of Medicine paper indexed on PubMed reported sustained, clinically relevant reduction in body weight, with adults with overweight or obesity losing a mean of 14.9 percent of baseline weight over 68 weeks.

In the SURMOUNT-1 trial of tirzepatide in participants with obesity or overweight without diabetes, the pivotal N Engl J Med SURMOUNT-1 paper indexed on PubMed reported substantial reductions in body weight loss of 15 percent at doses of 5 mg, 19.5 percent at 10 mg, and 20.9 percent at the higher dose of tirzepatide 15 mg over 72 weeks. The head-to-head SURPASS-2 trial in adults with type 2 diabetes was the first randomized clinical study comparing tirzepatide to semaglutide directly: tirzepatide compared favourably and was reported as superior to semaglutide on both glycemic and weight endpoints, with greater weight loss than semaglutide across the dose range. A 2024 Diabetes Care systematic review and network meta-analysis of glucagon-like peptide-1 and dual-agonist therapies, comparing tirzepatide to semaglutide across clinical studies and weight loss in clinical trials, reaches the same direction of effect: tirzepatide offers larger weight reduction at the top doses, and tirzepatide and semaglutide may be combined sequentially in research protocols.

How quickly does weight loss happen?

Both molecules produce visible weight loss in adults within the first 12 weeks. According to a phase 2 trial of the agonist tirzepatide indexed in PubMed, tirzepatide induced a dose-dependent bodyweight loss ranging from 7 percent at lower doses to higher figures at the 15 mg dose, with the curve continuing to descend through 26 weeks before plateauing. In SURMOUNT-1, average weight loss approached 6 percent by week 12 and 14 percent by week 24 in the tirzepatide group (10 mg). For semaglutide, treatment with semaglutide in adults under the STEP-1 protocol showed roughly 6 percent loss at 12 weeks and 10 percent at 24 weeks; participants who administered semaglutide had visible weight loss by week 8. Time to lose 20 pounds on tirzepatide depends on baseline body weight loss and dose escalation but is typically reported at 12 to 20 weeks at the higher doses. Like semaglutide, tirzepatide works through incretin signalling, and the comparison of tirzepatide vs semaglutide on time-to-effect is dose-dependent. Patients in the semaglutide group of the STEP-1 trial reported the most common side effects in the first 8 weeks; the safety of tirzepatide tracks a similar early-window GI pattern.

Muscle loss with semaglutide or tirzepatide

Loss of lean mass with either compound mirrors what happens in any sustained caloric deficit. DEXA substudies in the STEP and SURMOUNT programs show that about 25 to 40 percent of total weight loss is fat-free mass when no resistance-training intervention is layered on. There is no consistent published evidence that semaglutide or tirzepatide produces more muscle loss than the other beyond what the magnitude of total weight loss predicts. Researchers running comparative trials should match for caloric deficit and resistance-training exposure rather than treating muscle loss as a drug-specific endpoint.

Side effects and adverse events

The adverse event profile of the two molecules is similar in shape and dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, and constipation. Discontinuation rates due to adverse events in the pivotal trials of semaglutide and tirzepatide cluster in the 4 to 7 percent range, with tirzepatide trending slightly higher at the 15 mg dose. Serious adverse events have included pancreatitis (rare), cholelithiasis (more common with greater rates of weight loss), and a thyroid C-cell tumour signal in rodents that has not been confirmed in humans.

Availability in Canada

Semaglutide is available in Canada as Ozempic (since 2018) and Wegovy (Wegovy launched in Canada in 2024). Tirzepatide became available in Canada in November 2024 as Mounjaro for type 2 diabetes; the Zepbound (weight-management) brand has not yet launched in Canada as of 2026. Research-only material for both peptides is sold by Canadian peptide suppliers under research-use-only labelling.

Switching between semaglutide and tirzepatide

There is no contraindication to switching tirzepatide or semaglutide in the published prescribing information. The practical considerations: the dose escalation schedule restarts, the gastrointestinal adverse event window often re-opens, and the early weeks on the new molecule will look slower than the steady-state of the previous one. Researchers running crossover designs should plan a washout of at least 5 weeks given the one-week half-life on both compounds and the secondary tail of the albumin-bound depot.

Semaglutide vs tirzepatide questions

Which is better for weight loss, semaglutide or tirzepatide?

Across the available evidence, tirzepatide produces larger average weight loss at the highest studied doses (about 20.9 percent at 15 mg) than semaglutide (about 14.9 percent at 2.4 mg). The SURPASS-2 head-to-head trial in type 2 diabetes places tirzepatide ahead on both weight and glycemic endpoints. For individual researchers and patients with type 2 diabetes or without type 2 diabetes, magnitude of expected reduction in body weight differs by dose and baseline weight.

How quickly can you expect to lose weight on tirzepatide?

Average weight loss of 6 percent is typical by 12 weeks at the 10 mg dose, 14 percent by 24 weeks, with the curve approaching a plateau around 60 to 72 weeks. Speed depends on the dose-escalation pace, baseline weight, and adherence.

Do you lose more muscle on semaglutide or tirzepatide?

There is no consistent published evidence that one produces more muscle loss than the other beyond what total weight loss predicts. DEXA substudies in both programs show 25 to 40 percent of weight loss is fat-free mass without a resistance-training intervention.

Is tirzepatide available in Canada?

Yes. Mounjaro launched in Canada in November 2024 for type 2 diabetes. The Zepbound brand has not yet launched in Canada as of 2026, so prescribers writing for weight management currently use the Mounjaro product off-label or as part of a clinical-trial protocol.

What are the key differences between semaglutide and tirzepatide?

Semaglutide is a pure GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide has two amino acid substitutions relative to native GLP-1; tirzepatide is a 39-residue chimeric peptide. In comparison studies, tirzepatide produces larger weight reduction and a slightly higher gastrointestinal adverse event rate at the top doses.

Key data point: The SURPASS-2 head-to-head trial (Frias et al., 2021, NEJM) showed Tirzepatide 15 mg produced 5.5 kg greater weight loss than Semaglutide 1 mg at 40 weeks (-12.4 kg vs -6.9 kg), with 40% greater HbA1c reduction — the first large RCT demonstrating that dual GIP/GLP-1 agonism produces clinically superior metabolic outcomes to single-mechanism GLP-1 agonism at approved doses.

Summary

Semaglutide and tirzepatide are the two most consequential incretin therapeutics in the treatment of obesity and type 2 diabetes. They differ in receptor pharmacology (single vs dual agonist), magnitude of weight reduction in clinical trials (about 15 percent vs about 21 percent at top doses), and current Canadian availability. Both produce sustained, clinically relevant reduction in body weight in adults with overweight or obesity, both share a GI-dominant adverse event profile, and both are research-relevant peptides for studies of incretin pharmacology, glycemic control, and weight management. Choose the comparison endpoint first, then match the molecule and dose to the question.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption. Not for diagnostic or therapeutic use.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.